BrilliantStrings offers a next‑generation injectable therapeutic, CHC™, which delivers densely packed, liquid‑crystal human collagen directly to musculoskeletal injuries such as tendon and rotator cuff tears. Using ultrasound‑guided administration, the mechanotherapeutic platform provides controlled collagen release to accelerate extracellular matrix repair and reduce the need for surgery.
Funding
Funding not disclosed
Founders
Product
Problem
Musculoskeletal injuries such as rotator cuff tears and tendon degeneration often require surgical intervention because existing treatments cannot deliver sufficient collagen directly to the damaged tissue, leading to prolonged recovery and limited healing outcomes.
Solution
BrilliantStrings has developed CHC™, a complete human collagen (CHC™) formulated as a densely packed liquid‑crystal injectable. The product is administered under ultrasound guidance, allowing the collagen solution to home to the injury site and release collagen in a controlled manner. By providing a mechanotherapeutic that directly supplements the extracellular matrix, CHC™ aims to accelerate tissue repair and reduce the need for surgery. The platform leverages proprietary manufacturing and targeting technologies to maintain collagen stability and ensure precise delivery to connective tissues.
Target Audience
Primary customers are orthopedic surgeons, sports medicine physicians, and rehabilitation clinics seeking non‑surgical options for tendon and rotator cuff repair.
Features
- Injectable formulation of full-length human collagen (CHC™) for direct application to musculoskeletal injuries
- Densely packed liquid‑crystal delivery matrix that protects collagen integrity and enables controlled release
- Ultrasound‑guided administration for accurate placement at the injury site
- Mechanotherapeutic action that supports rapid extracellular matrix reconstruction and tendon repair
- Scalable manufacturing process based on decades of extracellular matrix mechanochemistry research